Randomised, placebo-controlled trial to evaluate co-trimoxazole to reduce mortality and morbidity in HIV-infected post-natal women in Zambia (TOPAZ);Essai randomisé placebo contrôlé pour évaluer la réduction de la mortalité et de la morbidité par le cotrimoxazole chez les femmes infectées par le VIH après l'accouchement en Zambie (TOPAZ)

Tropical Medicine and International Health

Volumn 16, Issue 4, 2011, Pages 518-526

  Nunn, Andrew J ^a,b,d   Mwaba, Peter B ^b,c,d   Chintu, Chifumbe ^b,c,d   Crook, Angela M ^a,b,d   Darbyshire, Janet H ^a,b,d   Ahmed, Yusuf ^b,c,d   Zumla, Alimuddin I ^b,d  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c UNIVERSITY OF ZAMBIA   (Zambia)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Africa; Bacterial infections; Cotox; HIV AIDS; Post natal; Prophylaxis; Women

Indexed keywords

COTOX; COTRIMOXAZOLE; GENTAMICIN; PENICILLIN G; PLACEBO; PREDNISOLONE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTICS; BACTERIAL DISEASE; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MORTALITY; WOMENS HEALTH;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILDBIRTH; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; JAUNDICE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ZAMBIA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; MEDICATION ADHERENCE; POSTNATAL CARE; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; YOUNG ADULT;

LUSAKA [ZAMBIA]; ZAMBIA;

BACTERIA (MICROORGANISMS);

EID: 79952762874     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2011.02731.x     Document Type: Article

References (32)

1. Ahmed Y, Mwaba P, Chintu C, Grange JM & Zumla A (1999) A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. The International Journal of Tuberculosis and Lung Disease 3, 675-680.
2. Alkatout I, Vineberg R, Schulz U, Anlauf M & Thistle P (2007) Continuation with cotox prophylaxis for the prevention of opportunistic infections in HIV-infected persons in rural Zimbabwe: feasibility, obstacles and opportunities. AIDS Care 19, 478-481.
3. Anglaret X, Chêne G, Attia A et al. (1999) Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 353, 1463-1468.
4. Ansari NA, Kombe AH, Kenyon TA et al. (2002) Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. The International Journal of Tuberculosis and Lung Disease 6, 55-63.
5. Bortolotti V & Buve A (2002) Prophylaxis of opportunistic infections in HIV-infected adults in sub-Saharan Africa: opportunities and obstacles. AIDS 16, 1309-1317.
6. Brou H, Desgardes-du-Lou A, Souville M et al. (2003) Prophylactic use of cotox against opportunistic infections in HIV-positive patients: knowledge and practices of health care providers in Ivory Coast. AIDS Care 15, 629-637.
7. Chintu C, Mudenda V, Lucas S et al. (2002) Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 360, 985-990.
8. Chintu C, Bhat GJ, Walker AS et al. (2004) Cotox prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double blind randomised placebo-controlled trial. Lancet 364, 1865-1871.
9. Colindres P, Mermin J, Ezati E et al. (2008) Utilisation of a basic care and prevention package in HIV-infected persons in Uganda. AIDS Care 20, 139-145.
10. Felkin DR, Feldman C, Schuchat A et al. (2004) Global strategies to prevent bacterial pneumonia in adults with HIV disease. The Lancet Infectious Diseases 4, 445-455.
11. Fylkesnes K, Musonda RM, Kasumba K et al. (1997) The HIV epidemic in Zambia: socio-demographic prevalence patterns and indications of trends among childbearing women. AIDS 11, 339-345.
12. Grant AD, Charalambous S, Fielding KL et al. (2005) Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomised incremental recruitment study. JAMA 293, 2719-2725.
13. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D & Gilks CF (2005) Effectiveness of cotox prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 19, 163-168.
14. Gwanzura L, Pasi C, Nathoo KJ et al. (2003) Rapid emergence of resistance to penicillin and trimethoprim-sulphamethoxazole in invasive Streptococcus pneumonia in Zimbabwe. International Journal of Antimicrobial Agents 21, 557-561.
15. Hammel MJ, Greene C, Chiller T et al. (2008) Does cotox prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? American Journal of Tropical Medicine and Hygiene 79, 320-330.
16. Hirshtick RE, Glassroth J, Jordan MC et al. (1995) Bacterial pneumonia in persons infected with the Human immunodeficiency virus. The New England Journal of Medicine 333, 845-851.
17. Lucas SB, Hounnou A, Peacock C et al. (1993) The mortality and pathology of HIV infection in a West African city. AIDS 7, 1569-1579.
18. Lynen L, Jacobs J & Colebunders R (2007) Cotox prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough? Transactions of the Royal Society of Tropical Medicine and Hygiene 101, 1050-1060.
19. Maynart M, Lièvre L, Sow PS et al. (2001) Primary prevention with cotox for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. Journal of Acquired Immune Deficiency Syndromes 26, 130-136.
20. Mermin J, Lule J, Ekwaru JP et al. (2004) Effect of cotox prophylaxis on morbidity, mortality, CD4 cell count and viral load in HIV infection in rural Uganda. Lancet 364, 1428-1434.
21. Murray J (2000) What to do until HAART arrives? The International Journal of Tuberculosis and Lung Disease 6, 1035-1037.
22. Mwansa J, Mutela K, Zulu I, Amadi B & Kelly P (2002) Antimicrobial sensitivity in enterobacteria from AIDS patients, Zambia. Emerging Infectious Diseases 8, 92-93.
23. Nunn A, Mwaba P, Mwinga A et al. (2008) Role of cotox prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 337, a257. DOI:
24. Palella FJ Jr, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 338, 853-860.
25. Quinn TC (2008) HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS (Suppl. 3), S7-S12.
26. Romogale MR, Moodley J & Sebiloane MH (2007) HIV-associated maternal mortality-primary causes of death at King Edward VIII Hospital, Durban. South African Medical Journal 97, 363-366.
27. StataCorp (2007) Stata Statistical Software: Release 10, StataCorp, College Station, TX.
28. Walson JL, Brown ER, Tieno PA et al. (2007) Morbidity among HIV-1 infected mothers in Kenya: prevalence and correlates of illness during 2 -year postpartum follow-up. Journal of Acquired Immune Deficiency Syndromes 46, 208-215.
29. Wiktor SZ, Sassan-Morokro M, Grant AD et al. (1999) Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 353, 1469-1475.
30. World Health Organization (2000) WHO/UNAIDS Report: Joint United Nations Programme on HIV/AIDS, Provisional WHO/UNAIDS Secretariat Recommendations on the Use of Cotox Prophylaxis in Adults and Children Living with HIV/AIDS in Africa. UNAIDS, Geneva. Available at:
31. World Health Organization (2006) WHO Expert Consultation on Cotox Prophylaxis in HIV Infection. WHO, Geneva. Available at:
32. Zachariah R, Harries AD, Spielmann MP et al. (2002) Changes in Escherichia coli resistance to cotox in tuberculosis patients and in relation to cotox prophylaxis in Thylo, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 202-204.